Potassium (chloride vs citrate vs gluconate) trials recruiting now
27 registrations that name potassium as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 27 registrations
Status
Phase
17US sites across 7 states
1
2 to 4
5 to 19
20 or more
All 27 registrations
RecruitingNCT07238400
Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia
Phase 2
Massachusetts General Hospital
About 90 people
Started Mar 20, 2026
In plain words A Phase 2 study of potassium in female participants 18 to 65, run by Massachusetts General Hospital. It plans to enroll about 90 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 65. Conditions: Hypertension.
Female with a history of preeclampsia (defined by ACOG criteria) in a singleton pregnancy without pre-gestational chronic hypertension.
Current chronic hypertension (stage 1 or greater).
Evidence of concentric left ventricular (LV) remodeling, defined as relative LV wall thickness >0.42, with or without LV hypertrophy.
The goal of this clinical trial is to determine if the medication eplerenone yields greater improvements in coronary microvascular function than chlorthalidone in women who experienced preeclampsia during pregnancy and subsequently developed chronic hypertension. The main Aims are: * To test the hypothesis that, in women with prior preeclampsia, current chronic hypertension, and concentric LV remodeling, eplerenone improves coronary microvascular function vs. chlorthalidone. The full summary is on the listing.
Where, as registered
2 US sites in 1 state.
RecruitingNCT06335537
Impact of Sodium Bicarbonate on 24-hour Urine Parameters in Hypocitriuric and Uric Acid Stone Formers
Phase 1
University of California, Irvine
About 100 people
Started May 1, 2025
In plain words A Phase 1 study of potassium in people 18 to 80, run by University of California, Irvine. It plans to enroll about 100 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Uric Acid Stones.
> 18 years of age and < 80 years of age,
Hypocitriuric (<320 mg/24 hours), Calcium Oxalate Stone or Uric Acid stone formers, currently on Urocit-K therapy as the standard of care.
The exclusion criteria are on the listing.
What it tests, as registered
Potassium citrate; Sodium bicarbonate
Registered summary
The incidence of kidney stone disease continues to rise globally. Although the treatment of kidney stone disease has dramatically improved in recent years, surgical management remains invasive and expensive. Patients who develop kidney stones are at high risk of recurrence during their lifetime; therefore, prevention of stones should be a primary focus. Low levels of citrate and acidic urine are risk factors for the formation of kidney stones such as calcium oxalate and uric acid, respectively. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07681050
Phosphate in Acute Pancreatitis
Phase 2
Duke University
About 100 people
Started Jul 9, 2026
In plain words A Phase 2 study of potassium in people 18 and older, run by Duke University. It plans to enroll about 100 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Pancreatitis.
Age 18 years or older
Presenting to the emergency department (ED) with acute pancreatitis meeting 2 or more characteristics of: (1) typical, persistent, severe upper abdominal pain, (2) lipase or amylase levels at least three times greater than the upper limit…
Trial treatment can be initiated within 24 hours of hospital admission
Consent can be obtained from the patient or their legal representative
The exclusion criteria are on the listing.
What it tests, as registered
Sodium Phosphate; Potassium Phosphate
Registered summary
The goal of this study is to learn if phosphate administration works to treat acute pancreatitis in adults presenting to the emergency department at Duke University Hospital. The main questions it aims to answer are: * Does having low phosphate levels increase the risk of acute pancreatitis and can giving phosphate through an IV make the illness less severe? * Is phosphate therapy practical to use, and what is the appropriate dose? * Is this study achievable, and how can the results help design a future randomized controlled trial to assess safety and effectiveness? Participants will: *… The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT05593055
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
Phase 4
Brigham and Women's Hospital
About 75 people
Started Aug 25, 2023
In plain words A Phase 4 study of potassium in people 18 to 75, run by Brigham and Women's Hospital. It plans to enroll about 75 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Hypertension; Left Ventricular Hypertrophy.
History of hypertension
Seated systolic BP < 180 mmHg and diastolic < 110 mmHg if on antihypertensives
Seated systolic BP 141-200 mmHg and/or diastolic BP 90-114 mmHg if not on antihypertensives
LVH by echocardiogram
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Eplerenone; Chlorthalidone; Potassium
Registered summary
The investigators' goal is to show that in hypertensive men and women with left ventricular hypertrophy (LVH) treatment with a mineralocorticoid receptor (MR) antagonist, versus a thiazide-like diuretic, will improve coronary microvascular function and cardiac efficiency, which will associate with improvements in LV structure and function. The investigators will achieve this through a randomized, controlled, basic experimental study involving humans (BESH).
Where, as registered
1 US site in 1 state.
RecruitingNCT04913805
Matching Perfusion and Metabolic Activity in HFpEF
Phase 2
University of Pennsylvania
About 53 people
Started Oct 11, 2021
In plain words A Phase 2 study of potassium in people 18 and older, run by University of Pennsylvania. It plans to enroll about 53 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Heart Failure With Preserved Ejection Fraction.
NYHA Class II-III symptoms
Left ventricular ejection fraction >= 50%
Stable medical condition for at least 2 weeks, as per investigator judgment
Prior or current evidence for elevated filling pressures as follows: a. Mitral early (E)/mitral septal tissue annular (e') velocity ratio > 8, in the context of a septal e' velocity <=7, in addition to one of the following: i.
This study will test whether pharmacologic agents that increase perfusion \[Potassium Nitrate (KNO3)\], with and without additional supplements that may improve mitochondrial function \[Propionyl-L-Carnitine (PLC) and Nicotinamide Riboside (NR)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
Where, as registered
1 US site in 1 state.
RecruitingNCT05138575
SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
Phase 2
University of Pennsylvania
About 53 people
Started Jan 24, 2022
In plain words A Phase 2 study of potassium in people 18 and older, run by University of Pennsylvania. It plans to enroll about 53 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Heart Failure With Preserved Ejection Fraction.
This study will test whether pharmacologic agents that may improve mitochondrial function and energy fuel metabolism \[Empagliflozin (Empa)\], with and without additional supplements that increase perfusion and fatty acid oxidation \[Potassium Nitrate (KNO3)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
Where, as registered
1 US site in 1 state.
RecruitingNCT06062017
Potassium, Hydration, Cardiovascular, and Kidney Study (PHACKs)
No phase
Auburn University
About 40 people
Started Nov 6, 2024
In plain words A study of potassium in people 18 to 30, run by Auburn University. It plans to enroll about 40 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 30; healthy volunteers accepted. Conditions: Blood Pressure; Hydration; Vascular Disease Risk.
Between the ages of 18-30 years
Resting blood pressure no higher than 150/90 mmHg
BMI below 35 kg/m2
Free of any metabolic disease (e.g., diabetes) kidney disease, pulmonary disorders (e.g., COPD), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular), no autoimmune diseases, and no history of cancer.
The exclusion criteria are on the listing.
What it tests, as registered
Water and Potassium supplementation
Registered summary
Compared with White Adults, Non-Hispanic Black Adults are at an elevated risk of developing cardiovascular disease (CVD) and end stage chronic-kidney disease (CKD), two of the leading causes of death in the United States. Inadequate hydration status is associated with risk factors for both CVD and CKD. Prior data show that Black individuals are less likely to be adequately hydrated when compared with their White counterparts. Further, socioeconomic factors have been shown to influence hydration practices. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06467825
Effect of Sex on Orthostatic Intolerance and Cardiovascular Response During Lunar Descent and Ascent
No phase
National Aeronautics and Space Administration (NASA)
About 38 people
Started Aug 9, 2022
In plain words A study of potassium in people 25 to 55, run by National Aeronautics and Space Administration (NASA). It plans to enroll about 38 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 25 to 55; healthy volunteers accepted. Conditions: Healthy.
Pass a test subject screening facility modified Air Force Class III physical
The purpose of Lunar OI (Orthostatic Intolerance) is to determine if there are differences between males and females in tolerance to and cardiovascular responses during different angles of head-up tilt simulating gravity levels less than or equal to Earth's gravity. Also, this study will determine if a gradient compression garment affects tolerance to tilting and the cardiovascular stress at different tilt angles. Males and females are being identified by biological sex. This will be a two-phased study design. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06003348
Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones
Phase 4
University of Texas Southwestern Medical Center
About 25 people
Started Dec 13, 2023
In plain words A Phase 4 study of potassium in people 21 to 99, run by University of Texas Southwestern Medical Center. It plans to enroll about 25 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 99. Conditions: Calcium Phosphate Kidney Stones.
What it tests, as registered
OHCit- standard dose; Potassium Citrate; Placebo; OHCit- low dose
Registered summary
This study tests whether hydroxycitrate, a molecule closely related to citrate, can reduce calcium phosphate stone recurrence.
Where, as registered
1 US site in 1 state.
RecruitingNCT07127705
Rapid Response of Stem Cells and Immune Cells for Efficacy
No phase
Natural Immune Systems Inc
About 24 people
Started May 21, 2025
In plain words A study of potassium in people 18 to 75, run by Natural Immune Systems Inc. It plans to enroll about 24 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75; healthy volunteers accepted. Conditions: Stem Cell Surveillance.
Healthy adults;
Age 18 - 75 years (inclusive);
BMI between 18.0 and 34.9 (inclusive);
Veins easy to see in one or both arms (to allow for the multiple blood draws);
6 more inclusion criteria and the exclusion criteria are on the listing.
The goal for this clinical trial is to compare rapid effects of four products on stem cells, immune activation, and mitochondrial function. A double-blind, placebo-controlled, cross-over study design will be used.
Where, as registered
1 US site in 1 state.
RecruitingNCT07294807
Pregnancy Salt Substitution Trial for Hypertensive Disorders of Pregnancy Prevention (PREG-Salt)
No phase
Peking University
About 3,200 people
Started Jan 6, 2026
In plain words A study of potassium in female participants 18 and older, run by Peking University. It plans to enroll about 3,200 people at 110 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Hypertensive Disorders of Pregnancy.
Singleton pregnancy with a viable fetus at ≤16 weeks of gestation.
Meets at least one of the following criteria (enrolled sequentially):
Systolic Blood Pressure (SBP) ≥130 mmHg and <160 mmHg at enrollment, OR current monotherapy with antihypertensive medications such as labetalol or nifedipine (priority enrollment).
At least one of the following 4 items: advanced maternal age (≥35 years), pre-pregnancy obesity (BMI ≥28 kg/m²), history of preeclampsia, or pre-existing type 1 or type 2 diabetes.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Potassium-enriched salt substitute; Usual salt
Registered summary
The PREG-Salt study is to evaluate the effect, safety and cost-effectiveness of low-sodium salt in reducing blood pressure and preventing hypertensive disorders in pregnant women at high risk in China. The study will recruit about 3,200 participants from approximately 100 hospitals across multiple provinces in China. Eligible pregnant women (≤16 weeks of gestation) will be randomly assigned in a 1:1 ratio to the following 2 groups: 1. Salt subsittute(intervention); 2. Usual salt (control) . The intervention will last until delivery. The study employs an adaptive two-phase design. The full summary is on the listing.
Where, as registered
No US site; China (110).
RecruitingNCT07165444
Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection
No phase
Tanta University
About 320 people
Started Sep 11, 2025
In plain words A study of potassium in people 18 and older, run by Tanta University. It plans to enroll about 320 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Potassium-Competitive Acid Blocker; Proton Pump Inhibitor; Bismuth Based Quadruple Therapy; Treatment; Helicobacter Pylori Infection.
Adults aged ≥18 years.
Both sexes.
Confirmed Helicobacter pylori infection by stool antigen (3rd-gen ELISA) or urea breath test (UBT).
This study aims to compare the eradication rate, safety, and patient adherence between potassium-competitive acid blockers (P-CABs) and proton pump inhibitor-based bismuth quadruple therapy in patients with Helicobacter pylori infection.
Where, as registered
No US site; Egypt (1).
RecruitingNCT06966635
Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets
Phase 4
Huashan Hospital
About 312 people
Started Apr 10, 2024
In plain words A Phase 4 study of potassium in people 18 to 70, run by Huashan Hospital. It plans to enroll about 312 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Hyperuricemia or Gout; Nephrolithiasis.
Meet the diagnostic criteria of the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) for gout in 2015
Age 18-70 years old, gender is not limited
The interval between the most recent acute onset of gout is at least > 2 weeks
Routine treatment with stable dose of uric-lowering drugs for > 4 weeks
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Sodium Bicarbonate Oral Capsule; Potassium Citrate Tablets; uric-acid-lowering drug
Registered summary
To evaluate whether alkalization has the effect of lowering uric acid and reducing gout flare and determine whether alkalization has a role in the prevention and treatment of urinary calculi in gout, the research participants were divided into the control group, the potassium citrate group and the sodium bicarbonate group. 2 alkalization groups took potassium citrate three times a day 2.16g each time, or sodium bicarbonate three times a day, 1.0g each time, on the basis of the standard uric acid-lowering treatment plan. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT06569589
Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat
Observational
Jens Titze
About 80 people
Started Dec 27, 2023
In plain words An observational study of potassium in people 21 to 70, run by Jens Titze. It plans to enroll about 80 people at 4 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 70. Conditions: Hypertension; Primary Aldosteronism; Hypokalemia.
Age 21-70 years, with arterial hypertension or suspected to have primary aldosteronism based on Endocrine Society Guidelines.
Male and female patients older than 21 years.
Willingness to participate and ability to provide informed consent.
The exclusion criteria are on the listing.
What it tests, as registered
23NaMRI Scan; Potassium Chloride (KCl)
Registered summary
The study aims to provide quantitative facts on the pathophysiological changes in tissue Na+ content during Na+/K+ redistribution disorders in patients with PA in response to standard therapy. The investigators hypothesize that patients with primary aldosteronism have excessive Na+ storage in the muscle, which can now be quantified non-invasively using 23NaMRI. The full summary is on the listing.
Where, as registered
No US site; Singapore (4).
RecruitingNCT07172425
Evaluation of Adding Nitrate Into Foods for Regulating Nitric Oxide Bioavailability in Healthy Individuals
No phase
Queen Mary University of London
About 30 people
Started Oct 15, 2025
In plain words A study of potassium in people 18 to 60, run by Queen Mary University of London. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60; healthy volunteers accepted. Conditions: Healthy Volunteers; Nitric Oxide; Vascular Function.
Healthy volunteer.
Aged ≥18 years and ≤ 60 years.
Willing to provide informed consent.
Able to understand and comply with protocol requirements, instructions, and stated restrictions.
Inorganic nitrate, found in leafy green vegetables and beetroot, can help lower blood pressure and support heart health. Early experimental work has suggested that dietary nitrate supplementation, in the form of beetroot juice or potassium nitrate capsules, can reduce blood pressure and improve endothelial function. Consequently, concentrated nitrate supplements like beetroot juice have become popular. However, these supplements can be expensive, high in sugar, and not to everyone's taste. The full summary is on the listing.
Where, as registered
No US site; United Kingdom (1).
RecruitingNCT07494266
Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited Potassium Content in Patients With Chronic Kidney Disease: A Pilot Study
No phase
Karolinska Institutet
About 30 people
Started Sep 29, 2026
In plain words A study of potassium in people 20 to 85, run by Karolinska Institutet. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 to 85. Conditions: Hyperkalemia; Chronic Kidney Disease (Stages 4 and 5).
Age between 20 and 85 years
Chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m²
Normal potassium levels (plasma potassium 3.5-5.3 mmol/L)
Not on dialysis
1 more inclusion criterion and the exclusion criteria are on the listing.
For many years, people with moderate to advanced chronic kidney disease (CKD) have been advised to limit their intake of potassium, a mineral found in many foods such as fruit, vegetables, legumes, whole grains, and nuts. The reason for this has been the risk of hyperkalemia, a condition in which the potassium level in the blood becomes too high and can be dangerous. In recent years, however, this view has been questioned. New research suggests that the link between potassium in food and high potassium levels in the blood may not be as clear as previously thought. The full summary is on the listing.
Where, as registered
No US site; Sweden (1).
RecruitingNCT07437430
Evaluation of Food Additive Contributions to Obesity: Pilot Study 1
No phase
McMaster University
About 20 people
Started Feb 10, 2026
In plain words A study of potassium in people 20 to 80, run by McMaster University. It plans to enroll about 20 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 to 80. Conditions: Obesity (Disorder).
Males and females age 20-80; BMI 30-39 kg/m2 inclusive; willingness and ability to follow the proposed study interventions and procedures; informed consent.
The exclusion criteria are on the listing.
What it tests, as registered
Potassium sorbate one-time administration followed by washout then placebo one-time administration; Placebo one-time administration followed by washout then potassium sorbate one-time administration
Registered summary
The effects of food additives on body weight in humans are largely unknown. This is a pilot cross-over double blind RCT in obese adults aimed to test the feasibility of measuring food consumption over 24 hours after one-time administration of K sorbate versus placebo after participants reduce the background consumption of related food additives.
Where, as registered
No US site; Canada (1).
Not yet recruitingNCT07408076
Sodium Bicarbonate as an Alternative to Potassium Citrate for Kidney Stones
Phase 1 and 2
University of California, Los Angeles
About 30 people
Starts Feb 1, 2026 (estimated)
In plain words A Phase 1 and 2 study of potassium in people 18 and older, run by University of California, Los Angeles. It plans to enroll about 30 people at 6 sites, 4 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Kidney Stones, Urolithiasis, Hypocitraturia; Nephrolithiasis.
Adult >18 years of age
History of nephrolithiasis
One 24h urine collections within one year of enrollment with hypocitraturia.
Patients currently utilizing or considering use of Kcit for stone prevention
The exclusion criteria are on the listing.
What it tests, as registered
Potassium Citrate; Sodium Bicarbonate
Registered summary
Kidney stones affect 1 in every 11 people in the US each year. In patients with kidney stones who are prescribed medications for stone management, only 30.2% are adherent to a medication regime and even fewer, only 13.4 % are adherent with citrate medications. Prescription potassium citrate can be expensive for many patients, leading to non-compliance. Sodium bicarbonate is a potential medication alternative that is cheaper and can potentially alkalinize the urine and/or decrease the risk of future kidney stones. The full summary is on the listing.
Where, as registered
4 US sites in 2 states; also Canada (1), Iceland (1).
Not yet recruitingNCT04651088
Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet
Early phase 1
University of Texas Southwestern Medical Center
About 15 people
Starts Jul 1, 2026 (estimated)
In plain words An early phase 1 study of potassium in people 18 to 90, run by University of Texas Southwestern Medical Center. It plans to enroll about 15 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 90; healthy volunteers accepted. Conditions: Kidney Stone.
The purpose of this study is to compare over the counter and alternative prescription urinary alkalinizing agents to slow release potassium citrate in their ability to modify urinary parameters associated with stone formation.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07788742
Efficacy of Potassium-Competitive Acid Blockers in Barrett's Esophagus (PCAB BE Study)
Phase 4
University of North Carolina, Chapel Hill
About 12 people
Starts Aug 31, 2026 (estimated)
In plain words A Phase 4 study of potassium in people 18 and older, run by University of North Carolina, Chapel Hill. It plans to enroll about 12 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Barrett Esophagus.
Adults aged 18 or older at time of consent.
Able to read and understand English and provide written informed consent.
History of Gastroesophageal Reflux Disease (GERD) with or without heartburn.
Diagnosed with nondysplastic Barrett's Esophagus (NBDE) defined as meeting the following within the past 3 years:
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Potassium-Competitive Acid Blockers (PCABs)
Registered summary
This is a research study to look at how a new medication compares to standard treatment for reducing acid reflux in patients with Barrett's Esophagus. The study drug is Vonoprazan. This is a pill that is not yet FDA-approved for this purpose in this patient population. The participants will first continue their current acid-reducing medicine (PPI) once a day for at least 7 days. After that, they will have a test to measure acid levels in their esophagus (food tube) while still taking the PPI medication. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07469722
POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure
Phase 2 and 3
Hospital de Clinicas de Porto Alegre
About 128 people
Starts Mar 23, 2026 (estimated)
In plain words A Phase 2 and 3 study of potassium in people 18 and older, run by Hospital de Clinicas de Porto Alegre. It plans to enroll about 128 people at 1 site, none in the US.
Acute decompensated heart failure (ADHF) is a frequent cause of hospitalization and is associated with high morbidity and mortality. Congestion is the primary pathophysiological mechanism leading to clinical deterioration and hospitalization in ADHF. Diuretics remain the cornerstone of treatment for most ADHF phenotypes; however, evidence regarding optimal strategies to guide diuretic therapy during the decongestion process is limited. The full summary is on the listing.
Where, as registered
No US site; Brazil (1).
Not yet recruitingNCT07576257
OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosili-cate in Heart Failure -Extension (OPRA-HF Extension)
Phase 2
Sahlgrenska University Hospital
About 110 people
Starts Sep 1, 2026 (estimated)
In plain words A Phase 2 study of potassium in people 70 and older, run by Sahlgrenska University Hospital. It plans to enroll about 110 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 70 and older. Conditions: Heart Failure.
1\. >70 yrs. 2. Regardless of LVEF but EF measured within past 2 years. For HFpEF echo criteria defined by ≥2 of: LV wall thickness ≥ 12 mm; LV mass index (BSA indexed LVH): male >115 g/m2, female >95 g/m2; relative wall thickness ≥0.42;…
Prior hyperkalemia (S-K> 5.0 mmol/L or P-K> 4.8 mmol/L*) during MRA treatment within last 24 months, and current S-K ≤ 5.0 or P-K ≤ 4.8 mmol/L
Current S-K 4.5-5.0 mmol/L or P-K 4.3-4.8 mmol/L, and potential risk of hyperkalemia as indicated by eGFR 30-45 ml/min/1,73 m2
Current S-K 5.1-5.9 mmol/L or P-K 4.9-5.7 mmol/L
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
potassium binder
Registered summary
A multicenter, randomized, controlled study in Sweden (n=110). This study consists of 2 phases: 1) open-label run-in within approximately 2 months, and 2) randomized, double-blinded and placebo-controlled treatment for 6 months. The open-label phase, in turn, consists of three periods: up-titration (normally 1 - 2 weeks, and longer in some cases), correction (maximum 72 hours) and maintenance (4 - 7 weeks).
Where, as registered
No sites listed yet.
Not yet recruitingNCT07178964
POTASSIUM-RICH SALT SUBSTITUTES IN KIDNEY TRANSPLANT RECIPIENTS
No phase
University Medical Centre Ljubljana
About 80 people
Starts Oct 1, 2025 (estimated)
In plain words A study of potassium in people 18 and older, run by University Medical Centre Ljubljana. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Hypertension Arterial; Kidney Transplant.
patients with a transplanted kidney ≥ 3 months post kidney-transplant
a functioning transplanted kidney with estimated glomerular filtration rate (eGFR) according to CKD/EPI equation of at least 25 ml/min
Elevated blood pressure/hypertension at the time of examination at the Kidney Transplantation Center outpatient clinic, determined by standardized blood pressure measurement (RR ≥ 130/80 mmHg)
Age ≥ 18 years
The exclusion criteria are on the listing.
What it tests, as registered
Potassium-enriched salt-substitute; Regular table salt
Registered summary
Excessive sodium intake and inadequate potassium intake in the diet are known risk factors for the development of arterial hypertension and an increased risk of cardiovascular events. Data from randomized controlled trials show that the use of salt substitutes with reduced sodium and increased potassium content represent an effective way to reduce dietary sodium intake, blood pressure and the occurrence of cardiovascular events. The full summary is on the listing.
Where, as registered
No US site; Slovenia (1).
Not yet recruitingNCT07027566
Effect of an Experimental Cannabidiol Gel on Tooth Sensitivity
Phase 1
Universidade Federal do Para
About 75 people
Starts Jul 25, 2025 (estimated)
In plain words A Phase 1 study of potassium in people 18 to 40, run by Universidade Federal do Para. It plans to enroll about 75 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 40. Conditions: Dentin Sensitivity.
Participants must have at least 28 teeth in the cavity
Good oral and general health
The exclusion criteria are on the listing.
What it tests, as registered
Potassium nitrate and sodium fluoride; Cannabidiol (CBD) Gel; Natrosol 4% Gel
Registered summary
The goal of this clinical trial will be to evaluate the effect applying an experimental gel based on cannabidiol oil (CBD) on tooth sensitivity induced by tooth bleaching with 35% hydrogen peroxide (HP). Volunteers will be selected and allocated to the following groups: GP - placebo gel, GCBD - experimental cannabidiol gel and GKF - Potassium Nitrate and Sodium Fluoride Gel. In each group, the corresponding desensitizing gel will be applied to on the teeth for 10 minutes. All groups will then undergo in-office whitening treatment with 35% hydrogen peroxide. The full summary is on the listing.
Where, as registered
No US site; Brazil (1).
Not yet recruitingNCT06871709
Clinical and Radiographic Evaluation of Potassium Nitrate in Polycarboxylate Versus Mineral Trioxide Aggregate in Vital Pulpotomy in Primary Molars
No phase
Cairo University
About 50 people
Starts May 30, 2025 (estimated)
In plain words A study of potassium in people 4 to 7, run by Cairo University. It plans to enroll about 50 people at 1 site, none in the US.
Children aged 4 to 7 years, in good general health.
Children with vital, deeply carious primary molars.
No history of spontaneous pain, pathological mobility, draining sinus tract, redness or swelling of the vestibule.
Normal gingival and periodontal condition, with no sensitivity to vestibular palpation, and no pain on percussion test.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Potassium Nitrate in Polycarboxylate cement; MTA-Anglus
Registered summary
The purpose of this RCT is to compare the clinical/radiographic outcomes of Potassium nitrate in polycarboxylate cement and MTA as pulpotomy biomaterials used for asymptomatic vital primary lower second molar and this will help to clinically evaluate the use of alternative material in vital pulpotomy in primary molars with deep carious cavities. Emphasis is set on avoiding total pupectomy and maintaining radicular pulp vitality therefore maintain the tooth in a viable condition till it's shedding and eruption of the permanent successor.
Where, as registered
No US site; Egypt (1).
Not yet recruitingNCT07202832
Urine Alkalinization for UTI in Women: RCT
No phase
Assiut University
About 50 people
Starts Oct 15, 2025 (estimated)
In plain words A study of potassium in female participants 18 to 50, run by Assiut University. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 50. Conditions: UTI - Urinary Tract Infection.
Women aged ≥ 18 and ≤ 50.
Symptoms of uncomplicated UTI or cystitis; including urinary frequency, urgency and dysuria.
Positive urine culture of mid-urine urine.
The exclusion criteria are on the listing.
What it tests, as registered
potassium citrate; Nitrofurantoin
Registered summary
The goal of this clinical trial is to evaluate whether urinary alkalinization using potassium citrate can relieve symptoms and improve urine culture results in women aged 18 to 50 years with uncomplicated urinary tract infections (UTIs). The main questions it aims to answer are: Does urinary alkalinization reduce UTI symptom scores by Day 7? Does it lead to better urine culture results compared to antibiotic? Researchers will compare urinary alkalinization with potassium citrate to antibiotic to see if it provides more symptom relief and better microbiological outcomes. The full summary is on the listing.
Where, as registered
No US site; Egypt (1).
Not yet recruitingNCT06819111
Role of Medication in Making Urine Less Acidic as Part of Kidney Stone Prevention
Phase 1
University of Texas Southwestern Medical Center
About 20 people
Starts Jul 1, 2026 (estimated)
In plain words A Phase 1 study of potassium in people 18 and older, run by University of Texas Southwestern Medical Center. It plans to enroll about 20 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Kidney Calculi.
adults, 18 years or older
recurrent stone formers or first-time stone formers at high risk for recurrence
have a baseline 24-hour urine within six months from study enrollment
have the ability to adhere to a directed diet
The exclusion criteria are on the listing.
What it tests, as registered
Potassium Citrate Extended Release Oral Tablet
Registered summary
Diet and medications are the cornerstones of kidney stone prevention. Potassium citrate is a commonly prescribed medication to help prevent kidney stones by making urine less acidic. There are different forms of potassium citrate such as over-the-counter tablet or powder, and slow-release tablets that require a prescription. However, it is unknown if one form is better than the others. Therefore, we want to compare different forms of potassium citrate and find out how well they work and whether patients prefer one form over the others. The full summary is on the listing.